<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766058006102-dece4bdb-0880-4fac-905b-c8bef0190c5e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvab094</link>
            <description><![CDATA[<p class="para" id="N65541">The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events, such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast-track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision-making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation, and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts, and the added value of artificial intelligence to achieve reliable advances.</p>]]></description>
            <pubDate><![CDATA[2021-04-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047335870-05062cfb-bf0c-4841-a915-d6616233ebb4/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa208</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">A hallmark of advanced atherosclerosis is inadequate immunosuppression by regulatory T (Treg) cells inside atherosclerotic lesions. Dyslipidemia has been suggested to alter Treg cell migration by affecting the expression of specific membrane proteins, thereby decreasing Treg cell migration towards atherosclerotic lesions. Besides membrane proteins, cellular metabolism has been shown to be a crucial factor in Treg cell migration. We aimed to determine whether dyslipidemia contributes to altered migration of Treg cells, in part, by affecting cellular metabolism.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">Dyslipidemia was induced by feeding <i>Ldlr</i><sup>−/−</sup> mice a western-type diet for 16–20 weeks and intrinsic changes in Treg cells affecting their migration and metabolism were examined. Dyslipidemia was associated with altered mTORC2 signalling in Treg cells, decreased expression of membrane proteins involved in migration, including CD62L, CCR7, and S1Pr1, and decreased Treg cell migration towards lymph nodes. Furthermore, we discovered that diet-induced dyslipidemia inhibited mTORC1 signalling, induced PPARδ activation and increased fatty acid (FA) oxidation in Treg cells. Moreover, mass-spectrometry analysis of serum from <i>Ldlr</i><sup>−/−</sup> mice with normolipidemia or dyslipidemia showed increases in multiple PPARδ ligands during dyslipidemia. Treatment with a synthetic PPARδ agonist increased the migratory capacity of Treg cells <i>in vitro</i> and <i>in vivo</i> in an FA oxidation-dependent manner. Furthermore, diet-induced dyslipidemia actually enhanced Treg cell migration into the inflamed peritoneum and into atherosclerotic lesions <i>in vitro</i>.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65576">Altogether, our findings implicate that dyslipidemia does not contribute to atherosclerosis by impairing Treg cell migration as dyslipidemia associated with an effector-like migratory phenotype in Treg cells.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa208-F7"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa208-F7');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766047335870-05062cfb-bf0c-4841-a915-d6616233ebb4/assets/cvaa208f7.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-07-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[The impact of aircraft noise on vascular and cardiac function in relation to noise event number: a randomized trial]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047285844-9839cae1-06a8-41dd-a600-b3aeeea4e65f/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa204</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Nighttime aircraft noise exposure has been associated with increased risk of hypertension and myocardial infarction, mechanistically linked to sleep disturbance, stress, and endothelial dysfunction. It is unclear, whether the most widely used metric to determine noise exposure, equivalent continuous sound level (<i>L</i><sub>eq</sub>), is an adequate indicator of the cardiovascular impact induced by different noise patterns.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65556">In a randomized crossover study, we exposed 70 individuals with established cardiovascular disease or increased cardiovascular risk to two aircraft noise scenarios and one control scenario. Polygraphic recordings, echocardiography, and flow-mediated dilation (FMD) were determined for three study nights. The noise patterns consisted of 60 (Noise60) and 120 (Noise120) noise events, respectively, but with comparable <i>L</i><sub>eq</sub>, corresponding to a mean value of 45 dB. Mean value of noise during control nights was 37 dB. During the control night, FMD was 10.02 ± 3.75%, compared to 7.27 ± 3.21% for Noise60 nights and 7.21 ± 3.58% for Noise120 nights (<i>P </i>&lt;<i> </i>0.001). Sleep quality was impaired after noise exposure in both noise scenario nights (<i>P </i>&lt;<i> </i>0.001). Serial echocardiographic assessment demonstrated an increase in the <i>E</i>/<i>E</i>′ ratio, a measure of diastolic function, within the three exposure nights, with a ratio of 6.83 ± 2.26 for the control night, 7.21 ± 2.33 for Noise60 and 7.83 ± 3.07 for Noise120 (<i>P </i>=<i> </i>0.043).</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65591">Nighttime exposure to aircraft noise with similar <i>L</i><sub>eq</sub>, but different number of noise events, results in a comparable worsening of vascular function. Adverse effects of nighttime aircraft noise exposure on cardiac function (diastolic dysfunction) seemed stronger the higher number of noise events.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa204-F5"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa204-F5');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766047285844-9839cae1-06a8-41dd-a600-b3aeeea4e65f/assets/cvaa204f5.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-10-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[NRF2 is a key regulator of endothelial microRNA expression under proatherogenic stimuli]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047276412-28a7db31-7b3f-4572-af84-7b78c11e657b/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa219</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Oxidized phospholipids and microRNAs (miRNAs) are increasingly recognized to play a role in endothelial dysfunction driving atherosclerosis. NRF2 transcription factor is one of the key mediators of the effects of oxidized phospholipids, but the gene regulatory mechanisms underlying the process remain obscure. Here, we investigated the genome-wide effects of oxidized phospholipids on transcriptional gene regulation in human umbilical vein endothelial cells and aortic endothelial cells with a special focus on miRNAs.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We integrated data from HiC, ChIP-seq, ATAC-seq, GRO-seq, miRNA-seq, and RNA-seq to provide deeper understanding of the transcriptional mechanisms driven by NRF2 in response to oxidized phospholipids. We demonstrate that presence of NRF2 motif and its binding is more prominent in the vicinity of up-regulated transcripts and transcriptional initiation represents the most likely mechanism of action. We further identified NRF2 as a novel regulator of over 100 endothelial pri-miRNAs. Among these, we characterize two hub miRNAs miR-21-5p and miR-100-5p and demonstrate their opposing roles on <i>mTOR</i>, <i>VEGFA</i>, <i>HIF1A</i>, and <i>MYC</i> expressions. Finally, we provide evidence that the levels of miR-21-5p and miR-100-5p in exosomes are increased upon senescence and exhibit a trend to correlate with the severity of coronary artery disease.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65569">Altogether, our analysis provides an integrative view into the regulation of transcription and miRNA function that could mediate the proatherogenic effects of oxidized phospholipids in endothelial cells.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa219-F8"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa219-F8');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766047276412-28a7db31-7b3f-4572-af84-7b78c11e657b/assets/cvaa219f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-07-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Sodium activates human monocytes via the NADPH oxidase and isolevuglandin formation]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047224517-644891b8-1ac2-4d8a-a065-a55c12322191/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa207</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Prior studies have focused on the role of the kidney and vasculature in salt-induced modulation of blood pressure; however, recent data indicate that sodium accumulates in tissues and can activate immune cells. We sought to examine mechanisms by which salt causes activation of human monocytes both <i>in vivo</i> and <i>in vitro</i>.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65557">To study the effect of salt in human monocytes, monocytes were isolated from volunteers to perform several <i>in vitro</i> experiments. Exposure of human monocytes to elevated Na<sup>+</sup><i>ex vivo</i> caused a co-ordinated response involving isolevuglandin (IsoLG)-adduct formation, acquisition of a dendritic cell (DC)-like morphology, expression of activation markers CD83 and CD16, and increased production of pro-inflammatory cytokines tumour necrosis factor-α, interleukin (IL)-6, and IL-1β. High salt also caused a marked change in monocyte gene expression as detected by RNA sequencing and enhanced monocyte migration to the chemokine CC motif chemokine ligand 5. NADPH-oxidase inhibition attenuated monocyte activation and IsoLG-adduct formation. The increase in IsoLG-adducts correlated with risk factors including body mass index, pulse pressure. Monocytes exposed to high salt stimulated IL-17A production from autologous CD4<sup>+</sup> and CD8<sup>+</sup> T cells. In addition, to evaluate the effect of salt <i>in vivo</i>, monocytes and T cells isolated from humans were adoptively transferred to immunodeficient NSG mice. Salt feeding of humanized mice caused monocyte-dependent activation of human T cells reflected by proliferation and accumulation of T cells in the bone marrow. Moreover, we performed a cross-sectional study in 70 prehypertensive subjects. Blood was collected for flow cytometric analysis and <sup>23</sup>Na magnetic resonance imaging was performed for tissue sodium measurements. Monocytes from humans with high skin Na<sup>+</sup> exhibited increased IsoLG-adduct accumulation and CD83 expression.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65586">Human monocytes exhibit co-ordinated increases in parameters of activation, conversion to a DC-like phenotype and ability to activate T cells upon both <i>in vitro</i> and <i>in vivo</i> sodium exposure. The ability of monocytes to be activated by sodium is related to <i>in vivo</i> cardiovascular disease risk factors. We therefore propose that in addition to the kidney and vasculature, immune cells like monocytes convey salt-induced cardiovascular risk in humans.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa207-F8"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa207-F8');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766047224517-644891b8-1ac2-4d8a-a065-a55c12322191/assets/cvaa207f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-07-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047212907-d393bb1b-516b-45b2-894a-64585536ad85/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa171</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Atherosclerotic vascular disease has an inflammatory pathogenesis. Heme from intraplaque haemorrhage may drive a protective and pro-resolving macrophage M2-like phenotype, Mhem, via AMPK and activating transcription factor 1 (ATF1). The antidiabetic drug metformin may also activate AMPK-dependent signalling. <i>Hypothesis:</i> Metformin systematically induces atheroprotective genes in macrophages via AMPK and ATF1, thereby suppresses atherogenesis.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65554">Normoglycaemic <i>Ldlr</i><sup>−/−</sup> hyperlipidaemic mice were treated with oral metformin, which profoundly suppressed atherosclerotic lesion development (<i>P</i> &lt; 5 × 10<sup>−11</sup>). Bone marrow transplantation from AMPK-deficient mice demonstrated that metformin-related atheroprotection required haematopoietic AMPK [analysis of variance (ANOVA), <i>P</i> &lt; 0.03]. Metformin at a clinically relevant concentration (10 μM) evoked AMPK-dependent and ATF1-dependent increases in <i>Hmox1</i>, <i>Nr1h2</i> (<i>Lxrb</i>), <i>Abca1</i>, <i>Apoe</i>, <i>Igf1</i>, and <i>Pdgf</i>, increases in several M2-markers and decreases in <i>Nos2</i>, in murine bone marrow macrophages. Similar effects were seen in human blood-derived macrophages, in which metformin-induced protective genes and M2-like genes, suppressible by si-ATF1-mediated knockdown. Microarray analysis comparing metformin with heme in human macrophages indicated that the transcriptomic effects of metformin were related to those of heme, but not identical. Metformin-induced lesional macrophage expression of p-AMPK, p-ATF1, and downstream M2-like protective effects.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65598">Metformin activates a conserved AMPK-ATF1-M2-like pathway in mouse and human macrophages, and results in highly suppressed atherogenesis in hyperlipidaemic mice via haematopoietic AMPK.</p></div>]]></description>
            <pubDate><![CDATA[2020-06-25T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766047202173-f58758d6-718c-4809-a98c-9087425f4991/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa205</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">A blood pressure (BP)-independent metabolic shift towards a catabolic state upon high sodium (Na<sup>+</sup>) diet, ultimately favouring body fluid preservation, has recently been described in pre-clinical controlled settings. We sought to investigate the real-life impact of high Na<sup>+</sup> intake on measures of renal Na<sup>+</sup>/water handling and metabolic signatures, as surrogates for cardiovascular risk, in hypertensive patients.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65560">We analysed clinical and biochemical data from 766 consecutive patients with essential hypertension, collected at the time of screening for secondary causes. The systematic screening protocol included 24 h urine (24 h-u-) collection on usual diet and avoidance of renin–angiotensin–aldosterone system-confounding medications. Urinary 24 h-Na<sup>+</sup> excretion, used to define classes of Na<sup>+</sup> intake (low ≤2.3 g/day; medium 2.3–5 g/day; high &gt;5 g/day), was an independent predictor of glomerular filtration rate after correction for age, sex, BP, BMI, aldosterone, and potassium excretion [<i>P</i> = 0.001; low: 94.1 (69.9–118.8) vs. high: 127.5 (108.3–147.8) mL/min/1.73 m<sup>2</sup>]. Renal Na<sup>+</sup> and water handling diverged, with higher fractional excretion of Na<sup>+</sup> and lower fractional excretion of water in those with evidence of high Na<sup>+</sup> intake [FE<sub>Na</sub>: low 0.39% (0.30–0.47) vs. high 0.81% (0.73–0.98), <i>P</i> &lt; 0.001; FE<sub>water</sub>: low 1.13% (0.73–1.72) vs. high 0.89% (0.69–1.12), <i>P</i> = 0.015]. Despite higher FE<sub>Na</sub>, these patients showed higher absolute 24 h Na<sup>+</sup> reabsorption and higher associated tubular energy expenditure, estimated by tubular Na<sup>+</sup>/ATP stoichiometry, accordingly [Δhigh–low = 18 (12–24) kcal/day, <i>P</i> &lt; 0.001]. At non-targeted liquid chromatography/mass spectrometry plasma metabolomics in an unselected subcohort (<i>n</i> = 67), metabolites which were more abundant in high versus low Na<sup>+</sup> intake (<i>P</i> &lt; 0.05) mostly entailed intermediates or end products of protein catabolism/urea cycle.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65620">When exposed to high Na<sup>+</sup> intake, kidneys dissociate Na<sup>+</sup> and water handling. In hypertensive patients, this comes at the cost of higher glomerular filtration rate, increased tubular energy expenditure, and protein catabolism from endogenous (muscle) or excess exogenous (dietary) sources. Glomerular hyperfiltration and the metabolic shift may have broad implications on global cardiovascular risk independent of BP.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa205-F4"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa205-F4');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1766047202173-f58758d6-718c-4809-a98c-9087425f4991/assets/cvaa205f4.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-07-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Highlights of American Heart Association Scientific Sessions 2020: a virtual experience]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765946469669-978b3969-9b4a-4018-9817-0eedf60fccc5/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa346</link>
            <description><![CDATA[]]></description>
            <pubDate><![CDATA[2021-01-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765907041440-3b7654ca-1988-43d2-a689-93c1cbe36f91/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa069</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">B cell functions in the process of atherogenesis have been investigated but several aspects remain to be clarified.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">In this study, we show that follicular regulatory helper T cells (T<sub>FR</sub>) control regulatory B cell (B<sub>REG</sub>) populations in Apoe<sup>−/−</sup> mice models on a high-cholesterol diet (HCD). Feeding mice with HCD resulted in up-regulation of T<sub>FR</sub> and B<sub>REG</sub> cell populations, causing the suppression of proatherogenic follicular helper T cell (T<sub>FH</sub>) response. T<sub>FH</sub> cell modulation is correlated with the growth of atherosclerotic plaque size in thoracoabdominal aortas and aortic root plaques, suggesting that T<sub>FR</sub> cells are atheroprotective. During adoptive transfer experiments, T<sub>FR</sub> cells transferred into HCD mice decreased T<sub>FH</sub> cell populations, atherosclerotic plaque size, while B<sub>REG</sub> cell population and lymphangiogenesis are significantly increased.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65590">Our results demonstrate that, through different strategies, both T<sub>FR</sub> and T<sub>FH</sub> cells modulate anti- and pro-atherosclerotic immune processes in an Apoe<sup>−/−</sup> mice model since T<sub>FR</sub> cells are able to regulate both T<sub>FH</sub> and B<sub>REG</sub> cell populations as well as lymphangiogenesis and lipoprotein metabolism.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa069-F7"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa069-F7');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765907041440-3b7654ca-1988-43d2-a689-93c1cbe36f91/assets/cvaa069f7.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-04-19T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Identification of an amino-terminus determinant critical for ryanodine receptor/Ca<sup>2+</sup> release channel function]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765906755036-1d29e91b-4fa9-410b-9d37-12928ccb5238/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa043</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims </h3><p class="para" id="N65545">The cardiac ryanodine receptor (RyR2), which mediates intracellular Ca<sup>2+</sup> release to trigger cardiomyocyte contraction, participates in development of acquired and inherited arrhythmogenic cardiac disease. This study was undertaken to characterize the network of inter- and intra-subunit interactions regulating the activity of the RyR2 homotetramer.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results </h3><p class="para" id="N65554">We use mutational investigations combined with biochemical assays to identify the peptide sequence bridging the β8 with β9 strand as the primary determinant mediating RyR2 N-terminus self-association. The negatively charged side chains of two aspartate residues (D179 and D180) within the β8–β9 loop are crucial for the N-terminal inter-subunit interaction. We also show that the RyR2 N-terminus domain interacts with the C-terminal channel pore region in a Ca<sup>2+</sup>-independent manner. The β8–β9 loop is required for efficient RyR2 subunit oligomerization but it is dispensable for N-terminus interaction with C-terminus. Deletion of the β8–β9 sequence produces unstable tetrameric channels with subdued intracellular Ca<sup>2+</sup> mobilization implicating a role for this domain in channel opening. The arrhythmia-linked R176Q mutation within the β8–β9 loop decreases N-terminus tetramerization but does not affect RyR2 subunit tetramerization or the N-terminus interaction with C-terminus. RyR2<sup>R176Q</sup> is a characteristic hypersensitive channel displaying enhanced intracellular Ca<sup>2+</sup> mobilization suggesting an additional role for the β8–β9 domain in channel closing.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion </h3><p class="para" id="N65572">These results suggest that efficient N-terminus inter-subunit communication mediated by the β8–β9 loop may constitute a primary regulatory mechanism for both RyR2 channel activation and suppression.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa043-F8"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa043-F8');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765906755036-1d29e91b-4fa9-410b-9d37-12928ccb5238/assets/cvaa043f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-02-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Human influenza A virus causes myocardial and cardiac-specific conduction
system infections associated with early inflammation and premature death]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765905823870-a5355d87-7efc-4fb8-8693-b643ff6c9ae8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa117</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Human influenza A virus (hIAV) infection is associated with important cardiovascular
complications, although cardiac infection pathophysiology is poorly understood. We aimed
to study the ability of hIAV of different pathogenicity to infect the mouse heart, and
establish the relationship between the infective capacity and the associated <i>in
vivo</i>, cellular and molecular alterations.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65555">We evaluated lung and heart viral titres in mice infected with either one of several
hIAV strains inoculated intranasally. 3D reconstructions of infected cardiac tissue were
used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells, and cardiac
vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection
and study underlying molecular alterations associated with the <i>in vivo</i>
electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and
replicated in cardiomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also
present in cardiac endothelial cells. Remarkably, lung viral titres did not
statistically correlate with viral titres in the mouse heart. The highly pathogenic
human recombinant virus PAmut showed faster replication, higher level of inflammatory
cytokines in cardiac tissue and higher viral titres in cardiac HL-1 mouse cells and
hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction
alterations were especially pronounced in PAmut-infected mice, associated with high
mortality rates, compared with PB2mut-infected animals. Consistently, connexin43 and
Na<sub>V</sub>1.5 expression decreased acutely in hiPSC-CMs infected with PAmut virus.
YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected
hiPSC-CMs compared with PB2mut-infected cells, consistent with mitochondrial
dysfunction. Human IAV infection did not increase myocardial fibrosis at 4-day
post-infection, although PAmut-infected mice showed an early increase in mRNAs
expression of lysyl oxidase.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65568">Human IAV can infect the heart and cardiac-specific conduction system, which may
contribute to cardiac complications and premature death.</p></div><p class="para" id="N65542">
<div class="section" id="ga1"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('ga1');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765905823870-a5355d87-7efc-4fb8-8693-b643ff6c9ae8/assets/cvaa117f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-05-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Loss of SIRT1 in diabetes accelerates DNA damage-induced vascular calcification]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765905158593-e0a21f2b-0d36-4f3f-9fb2-93edea35def9/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa134</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Vascular calcification is a recognized predictor of cardiovascular risk in the diabetic patient, with DNA damage and accelerated senescence linked to oxidative stress-associated pathological calcification. Having previously shown that systemic SIRT1 is reduced in diabetes, the aim was to establish whether SIRT1 is protective against a DNA damage-induced senescent and calcified phenotype in diabetic vascular smooth muscle cells (vSMCs).</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">Immunohistochemistry revealed decreased SIRT1 and increased DNA damage marker expression in diabetic calcified arteries compared to non-diabetic and non-calcified controls, strengthened by findings that vSMCs isolated from diabetic patients show elevated DNA damage and senescence, assessed by the Comet assay and telomere length. Hyperglycaemic conditions were used and induced DNA damage and enhanced senescence in vSMCs <i>in vitro</i>. Using H<sub>2</sub>O<sub>2</sub> as a model of oxidative stress-induced DNA damage, pharmacological activation of SIRT1 reduced H<sub>2</sub>O<sub>2</sub> DNA damage-induced calcification, prevented not only DNA damage, as shown by reduced comet tail length, but also decreased yH2AX foci formation, and attenuated calcification. While Ataxia Telanglectasia Mutated (ATM) expression was reduced following DNA damage, in contrast, SIRT1 activation significantly increased ATM expression, phosphorylating both MRE11 and NBS1, thus allowing formation of the MRN complex and increasing activation of the DNA repair pathway.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65572">DNA damage-induced calcification is accelerated within a diabetic environment and can be attenuated <i>in vitro</i> by SIRT1 activation. This occurs through enhancement of the MRN repair complex within vSMCs and has therapeutic potential within the diabetic patient.</p></div>]]></description>
            <pubDate><![CDATA[2020-05-13T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[
<i>MTMR4</i> SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765905126082-051229cd-0bb7-4e17-afec-3ec00546d4f3/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa019</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">In long QT syndrome (LQTS) patients, modifier genes modulate the arrhythmic risk associated with a disease-causing mutation. Their recognition can improve risk stratification and clinical management, but their discovery represents a challenge. We tested whether a cellular-driven approach could help to identify new modifier genes and especially their mechanism of action.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We generated human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) from two patients carrying the same <i>KCNQ1</i>-Y111C mutation, but presenting opposite clinical phenotypes. We showed that the phenotype of the iPSC-CMs derived from the symptomatic patient is due to impaired trafficking and increased degradation of the mutant KCNQ1 and wild-type human ether-a-go-go-related gene. In the iPSC-CMs of the asymptomatic (AS) patient, the activity of an E3 ubiquitin-protein ligase (Nedd4L) involved in channel protein degradation was reduced and resulted in a decreased arrhythmogenic substrate. Two single-nucleotide variants (SNVs) on the Myotubularin-related protein 4 (<i>MTMR4</i>) gene, an interactor of Nedd4L, were identified by whole-exome sequencing as potential contributors to decreased Nedd4L activity. Correction of these SNVs by CRISPR/Cas9 unmasked the LQTS phenotype in AS cells. Importantly, the same <i>MTMR4</i> variants were present in 77% of AS Y111C mutation carriers of a separate cohort. Thus, genetically mediated interference with Nedd4L activation seems associated with protective effects.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65566">Our finding represents the first demonstration of the cellular mechanism of action of a protective modifier gene in LQTS. It provides new clues for advanced risk stratification and paves the way for the design of new therapies targeting this specific molecular pathway.</p></div>]]></description>
            <pubDate><![CDATA[2020-03-16T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Hepatocyte growth factor-regulated tyrosine kinase substrate is essential for endothelial cell polarity and cerebrovascular stability]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765838505936-8c019ee5-488c-4cec-9be0-d52652797405/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa016</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Hepatocyte growth factor-regulated tyrosine kinase substrate (Hgs), a key component of the endosomal sorting complex required for transport (ESCRT), has been implicated in many essential biological processes. However, the physiological role of endogenous Hgs in the vascular system has not previously been explored. Here, we have generated brain endothelial cell (EC) specific <i>Hgs</i> knockout mice to uncover the function of Hgs in EC polarity and cerebrovascular stability.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65554">Knockout of <i>Hgs</i> in brain ECs led to impaired endothelial apicobasal polarity and brain vessel collapse in mice. We determined that Hgs is essential for recycling of vascular endothelial (VE)-cadherin to the plasma membrane, since loss of Hgs blocked trafficking of endocytosed VE-cadherin from early endosomes to recycling endosomes, and impaired the motility of recycling endosomes. Supportively, overexpression of the motor kinesin family member 13A (KIF13A) restored endosomal recycling and rescued abrogated polarized trafficking and distribution of VE-cadherin in Hgs knockdown ECs.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65563">These data uncover a novel physiological function of Hgs and support an essential role for the ESCRT machinery in the maintenance of EC polarity and cerebrovascular stability.</p></div>]]></description>
            <pubDate><![CDATA[2020-02-11T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Atrial fibrillation after cardiac surgery: to screen or not to screen?]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765822493454-f82376fe-0b1e-49d2-8700-3f1cb4d22a72/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa352</link>
            <description><![CDATA[]]></description>
            <pubDate><![CDATA[2021-01-18T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767786195-a8a4fe82-b014-4fcf-85f3-5a5ac782671a/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvz331</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Chronic pressure or volume overload induce concentric vs. eccentric left ventricular (LV) remodelling, respectively. Previous studies suggest that distinct signalling pathways are involved in these responses. NADPH oxidase-4 (Nox4) is a reactive oxygen species-generating enzyme that can limit detrimental cardiac remodelling in response to pressure overload. This study aimed to assess its role in volume overload-induced remodelling.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We compared the responses to creation of an aortocaval fistula (Shunt) to induce volume overload in <i>Nox4</i>-null mice (Nox4<sup>−/−</sup>) vs. wild-type (WT) littermates. Induction of Shunt resulted in a significant increase in cardiac Nox4 mRNA and protein levels in WT mice as compared to Sham controls. Nox4<sup>−/−</sup> mice developed less eccentric LV remodelling than WT mice (echocardiographic relative wall thickness: 0.30 vs. 0.27, <i>P</i> &lt; 0.05), with less LV hypertrophy at organ level (increase in LV weight/tibia length ratio of 25% vs. 43%, <i>P</i> &lt; 0.01) and cellular level (cardiomyocyte cross-sectional area: 323 µm<sup>2</sup> vs. 379 μm<sup>2</sup>, <i>P</i> &lt; 0.01). LV ejection fraction, foetal gene expression, interstitial fibrosis, myocardial capillary density, and levels of myocyte apoptosis after Shunt were similar in the two genotypes. Myocardial phospho-Akt levels were increased after induction of Shunt in WT mice, whereas levels decreased in Nox4<sup>−/−</sup> mice (+29% vs. −21%, <i>P</i> &lt; 0.05), associated with a higher level of phosphorylation of the S6 ribosomal protein (S6) and the eIF4E-binding protein 1 (4E-BP1) in WT compared to Nox4<sup>−/−</sup> mice. We identified that Akt activation in cardiac cells is augmented by Nox4 via a Src kinase-dependent inactivation of protein phosphatase 2A.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65590">Endogenous Nox4 is required for the full development of eccentric cardiac hypertrophy and remodelling during chronic volume overload. Nox4-dependent activation of Akt and its downstream targets S6 and 4E-BP1 may be involved in this effect.</p></div>]]></description>
            <pubDate><![CDATA[2019-12-10T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Junctophilin-2 tethers T-tubules and recruits functional L-type calcium channels to lipid rafts in adult cardiomyocytes]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767446035-fdd756a6-9e39-487e-838e-3f23712544a6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa033</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aim</h3><p class="para" id="N65545">In cardiomyocytes, transverse tubules (T-tubules) associate with the sarcoplasmic reticulum (SR), forming junctional membrane complexes (JMCs) where L-type calcium channels (LTCCs) are juxtaposed to Ryanodine receptors (RyR). Junctophilin-2 (JPH2) supports the assembly of JMCs by tethering T-tubules to the SR membrane. T-tubule remodelling in cardiac diseases is associated with downregulation of JPH2 expression suggesting that JPH2 plays a crucial role in T-tubule stability. Furthermore, increasing evidence indicate that JPH2 might additionally act as a modulator of calcium signalling by directly regulating RyR and LTCCs. This study aimed at determining whether JPH2 overexpression restores normal T-tubule structure and LTCC function in cultured cardiomyocytes.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">Rat ventricular myocytes kept in culture for 4 days showed extensive T-tubule remodelling with impaired JPH2 localization and relocation of the scaffolding protein Caveolin3 (Cav3) from the T-tubules to the outer membrane. Overexpression of JPH2 restored T-tubule structure and Cav3 relocation. Depletion of membrane cholesterol by chronic treatment with methyl-β-cyclodextrin (MβCD) countered the stabilizing effect of JPH2 overexpression on T-tubules and Cav3. Super-resolution scanning patch-clamp showed that JPH2 overexpression greatly increased the number of functional LTCCs at the plasma membrane. Treatment with MβCD reduced LTCC open probability and activity. Proximity ligation assays showed that MβCD did not affect JPH2 interaction with RyR and the pore-forming LTCC subunit Ca<sub>v</sub>1.2, but strongly impaired JPH2 association with Cav3 and the accessory LTCC subunit Ca<sub>v</sub>β2.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusions</h3><p class="para" id="N65563">JPH2 promotes T-tubule structural stability and recruits functional LTCCs to the membrane, most likely by directly binding to the channel. Cholesterol is involved in the binding of JPH2 to T-tubules as well as in the modulation of LTCC activity. We propose a model where cholesterol and Cav3 support the assembly of lipid rafts which provide an anchor for JPH2 to form JMCs and a platform for signalling complexes to regulate LTCC activity.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa033-F8"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa033-F8');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765767446035-fdd756a6-9e39-487e-838e-3f23712544a6/assets/cvaa033f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-02-13T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765767325059-5b418574-0dfe-40bd-99d5-fb0f4d5fd948/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvz345</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD).</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h intravenous infusion of serelaxin (30 µg/kg/day) or matching placebo. The primary endpoints were change from baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30, and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, <i>n </i>=<i> </i>25; placebo, <i>n </i>=<i> </i>26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of −9.6 mmHg (<i>P </i>=<i> </i>0.01) and −13.5 mmHg (<i>P </i>=<i> </i>0.0003) for systolic blood pressure and −5.2 mmHg (<i>P </i>=<i> </i>0.02) and −8.4 mmHg (<i>P </i>=<i> </i>0.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47 h in global MPR (−0.24 vs. −0.13, <i>P </i>=<i> </i>0.44) or AIx (3.49% vs. 0.04%, <i>P </i>=<i> </i>0.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, <i>n </i>=<i> </i>5; placebo, <i>n </i>=<i> </i>7) to 180-day follow-up.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65617">In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.</p></div>]]></description>
            <pubDate><![CDATA[2020-02-17T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Genetic lineage tracing reveals poor angiogenic potential of cardiac endothelial cells]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765766867434-45e07392-7ff3-425d-a4c8-f7d5141964b1/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa012</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Cardiac ischaemia does not elicit an efficient angiogenic response. Indeed, lack of surgical revascularization upon myocardial infarction results in cardiomyocyte death, scarring, and loss of contractile function. Clinical trials aimed at inducing therapeutic revascularization through the delivery of pro-angiogenic molecules after cardiac ischaemia have invariably failed, suggesting that endothelial cells in the heart cannot mount an efficient angiogenic response. To understand why the heart is a poorly angiogenic environment, here we compare the angiogenic response of the cardiac and skeletal muscle using a lineage tracing approach to genetically label sprouting endothelial cells.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We observed that overexpression of the vascular endothelial growth factor in the skeletal muscle potently stimulated angiogenesis, resulting in the formation of a massive number of new capillaries and arterioles. In contrast, response to the same dose of the same factor in the heart was blunted and consisted in a modest increase in the number of new arterioles. By using Apelin-CreER mice to genetically label sprouting endothelial cells we observed that different pro-angiogenic stimuli activated Apelin expression in both muscle types to a similar extent, however, only in the skeletal muscle, these cells were able to sprout, form elongated vascular tubes activating Notch signalling, and became incorporated into arteries. In the heart, Apelin-positive cells transiently persisted and failed to give rise to new vessels. When we implanted cancer cells in different organs, the abortive angiogenic response in the heart resulted in a reduced expansion of the tumour mass.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65557">Our genetic lineage tracing indicates that cardiac endothelial cells activate Apelin expression in response to pro-angiogenic stimuli but, different from those of the skeletal muscle, fail to proliferate and form mature and structured vessels. The poor angiogenic potential of the heart is associated with reduced tumour angiogenesis and growth of cancer cells.</p></div><p class="para" id="N65542">
<div class="section" id="cvaa012-F9"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('cvaa012-F9');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765766867434-45e07392-7ff3-425d-a4c8-f7d5141964b1/assets/cvaa012f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-01-30T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Regional and global contributions of air pollution to risk of death from
COVID-19]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765759801089-cfe50676-b8c0-4505-b9e3-0d44d7e32747/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa288</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">The risk of mortality from the coronavirus disease that emerged in 2019 (COVID-19) is
increased by comorbidity from cardiovascular and pulmonary diseases. Air pollution also
causes excess mortality from these conditions. Analysis of the first severe acute
respiratory syndrome coronavirus (SARS-CoV-1) outcomes in 2003, and preliminary
investigations of those for SARS-CoV-2 since 2019, provide evidence that the incidence
and severity are related to ambient air pollution. We estimated the fraction of COVID-19
mortality that is attributable to the long-term exposure to ambient fine particulate air
pollution.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We characterized global exposure to fine particulates based on satellite data, and
calculated the anthropogenic fraction with an atmospheric chemistry model. The degree to
which air pollution influences COVID-19 mortality was derived from epidemiological data
in the USA and China. We estimate that particulate air pollution contributed ∼15% (95%
confidence interval 7–33%) to COVID-19 mortality worldwide, 27% (13 – 46%) in East Asia,
19% (8–41%) in Europe, and 17% (6–39%) in North America. Globally, ∼50–60% of the
attributable, anthropogenic fraction is related to fossil fuel use, up to 70–80% in
Europe, West Asia, and North America.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65557">Our results suggest that air pollution is an important cofactor increasing the risk of
mortality from COVID-19. This provides extra motivation for combining ambitious policies
to reduce air pollution with measures to control the transmission of COVID-19.</p></div>]]></description>
            <pubDate><![CDATA[2020-10-26T00:00]]></pubDate>
        </item>
    </channel>
</rss>